Replies to post #15530 on BioCurex, Inc.(fka BOCX)

[Ted F]

Opp.Knocking you said"If Dr Moro is saying he will be using ADML as a precedent, he must be getting ready present to the FDA. He has been in discussions as he stated..."

Where did he say this. I found the following:

"We are researching the 510K approval of another company’s product called DR70 by the US FDA."

Researching does not constitute BOCX will actually be using ADML as a precedent.
Same old, same old, no?

One other thing. The June 12th press release states:

Manual tests (e.g. not performed in automated instruments) are excluded from the semi-exclusive limitation of BioCurex licensing agreements. This fact, together with the Company's development of the ubiquitous ELISA format, has prompted Biocurex to undertake the direct commercialization of its ELISA RECAF blood tests

So, BOCX is going forward without IMA, yes? Why and with who's money? Somehow I just don't see this happening.

[Gold Seeker]

Opportunity, if you had paid attention, you would have noticed in the DR70 application by AMDL, there were a lot of study results. If you had paid even more attention, you would have noticed the the application was made once before and rejected because of insufficient studies. Two years after the first rejection, it was finally approved.

Now, this was a 510(k) and not a PMA. Do you get the picture that you just don't license a test and a few months later be ready to apply to the FDA for approval. They would laugh at you and toss it back. They might even say, "we want a PMA".